Physician profile
Cher Diaz
NPI 1740843937
$9,473.69
in general payments reported to CMS, 2019-2025
27 companies · $2,188 in 2025
The $2,188 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $883 · 2022: $1,625 · 2023: $2,073 · 2024: $2,705 · 2025: $2,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,707 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,707.20 |
| Education | $259.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,093.59 | 2021-2025 | |
| Janssen Biotech, INC. | $1,298.96 | 2021-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,087.20 | 2021-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,073.40 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Ardelyx, INC. | $679.04 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $488.57 | 2024-2025 | Resmetirom, Rezdiffra |
| Lilly USA, LLC | $482.49 | 2023-2025 | Omvoh |
| Redhill Biopharma INC. | $334.19 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Janssen Scientific Affairs, LLC | $278.89 | 2022-2023 | Stelara |
| Aimmune Therapeutics, INC. | $272.00 | 2024-2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $200.13 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $184.30 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $183.78 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $169.25 | 2023-2025 | Ocaliva |
| Exact Sciences Corporation | $123.49 | 2023-2024 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $100.36 | 2022-2025 | Pancreaze |
| Braintree Laboratories, INC. | $92.97 | 2022-2025 | Suflave, Sutab |
| Novo Nordisk INC | $72.06 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Ipsen Biopharmaceuticals, INC | $48.33 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $36.47 | 2024 | Dificid |
| Evoke Pharma, INC. | $36.29 | 2023 | Gimoti |
| Organon LLC | $28.36 | 2024 | |
| Gilead Sciences, INC. | $27.36 | 2024 | |
| Ferring Pharmaceuticals INC. | $23.27 | 2024 | Rebyota |
| Celltrion USA INC. | $22.19 | 2025 | Vegzelma |
| Cepheid | $21.23 | 2025 | |
| Alfasigma USA, INC. | $15.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cher Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.